Barinthus Biotherapeutics plc – Material Contracts Watch

from 10-K 45 pages Lease Agreement

from 8-K 14 pages Lock-Up Agreement1

from 425 14 pages Lock-Up Agreement1

from 8-K 19 pages Voting and Support Agreement

from 425 19 pages Voting and Support Agreement

from 425 19 pages Voting and Support Deed

from 8-K 19 pages Voting and Support Deed

from 10-K 10 pages Preamble A.YOU Entered Into an Employment Agreement With the Company Dated 23 January 2023 (The Employment Agreement) as Amended From Time to Time. the Employment Agreement Is Governed by Swiss Law. B.DURING Your Employment Agreement, You Acted for the Company or Its Direct and Indirect Parent Companies, Their Subsidiaries and/or Any Associated and Affiliated Entities (Each a Group Company). C.ON 25 November 2024, You Informed the Company That You Decided to Step Down From Your Role as Cso of the Company and Wished to Leave the Company at a Mutually Agreed Date (Expected at the End of January 2025). D.THE Parties Intend to Continue Their Collaboration After the Mutually Agreed Termination Date Under an On-Call Employment Agreement Under Which You Will Continue to Provide Advice to the Company From Time to Time. E.THE Parties Intend to Settle All Modalities of the Termination of the Employment Agreement Amicably and on the Terms and Conditions of This Termination Agreement. Therefore, the Parties Enter Into the Following Agreement (The Termination Agreement): 1. Termination of Employment Agreement the Parties Agree to Terminate the Employment Agreement as of 3 February 2025 (The Termination Date). Any Extension of the Employment Agreement for Any Reason as Listed in Article 336c Para. 1 Co, Especially Due to Illness Pregnancy, Maternity or Accident, Shall Be Expressly Excluded. 1. Resignation

from 10-K 13 pages Employment Agreement

from 10-Q 23 pages This Agreement Is Made on 21 February 2024 Between (1) Barinthus Biotherapeutics plc Whose Registered Number Is 13282620 and Whose Registered Office Is at Unit 6-10, Zeus Building Rutherford Avenue, Harwell, Didcot, United Kingdom, Ox11 0df (The "Company"); and (2) Leonard Willem Frederik Hooftman (The "Executive"). It Is Agreed as Follows: 1. Definitions and Interpretation 1.1in This Agreement the Following Words and Expressions Shall Have the Following Meanings: "Associated Company" Means Any Entity Which From Time to Time Is a Parent Undertaking of the Company or a Subsidiary Undertaking of the Company or of Any Such Parent Undertaking Where “Subsidiary Undertaking” and “Parent Undertaking” Has the Meanings Given to Them in the Companies Act 2006. "Board" Means the Board of Directors of the Company From Time to Time

from 10-K 60 pages Certain Information Identified With [***] Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

from 10-Q 5 pages Barinthus Biotherapeutics Plc Compensation Recovery Policy Adopted as of November 9, 2023

from 10-Q 23 pages ​ Employment Agreement ​ ​ ​ Dated 23 January, 2023 ​ ​ ​ by and Between ​ ​ ​ /S/ William Enright ​ ​ Vaccitech Switzerland Gmbh ​ C/O Walder Wyss AG ​ Aeschenvorstadt 48 ​ 4051 Basel ​ Switzerland (The Company) ​ ​ and ​ /S/ Nadege Pelletier ​ Nadege Pelletier (The Employee) ​

from 10-Q 3 pages Dear [Name of Director or Officer], Vaccitech PLC (The “Company”) and Your Role as a Director/Officer of the Company

from 10-Q 29 pages Dated September 15, 2022 ​ (1)vaccitech PLC and (2)gemma Brown ​ Service Agreement ​ ​ ​

from 10-Q 11 pages Vaccitech plc Registration Rights Agreement

from 10-Q 147 pages Land Registry Prescribed Clauses

from S-1/A 13 pages Vaccitech plc 2021 Employee Share Purchase Plan

from S-1/A 29 pages Dated 2021 (1) Vaccitech plc and (2) Graham Griffiths Service Agreement Index

from S-1/A 27 pages Dated 2021 (1) Vaccitech plc and (2) Christopher Ellis Service Agreement